Technical Data
I7662-14P
Interferon beta 1 (beta 1a), Recombinant, Human (IFNb1, IFNb1a)
10ug
Molecular Biology Storage: -20CShipping: Blue Ice
Source:
Recombinant corresponding to 166aa of human Interferon-beta 1a expressed in CHO (Chinese Hamster Ovarian) cells is a single, glycosylated polypeptide chain.

Molecular Weight:
~22.5kD

Biological Activity:
The specific activity as determined in a viral resistance assay (human "Wish" cell line and VSV virus or the monkey VERO cell line with EMCV virus) was found to be 270x10^6 IU/mg.

Dimers and Aggregates:
1% (SDS-PAGE)

Protein Content:
Protein quantitation was carried out by two independent methods: 1. UV spectroscopy at 280nm. 2. Analysis by RP-HPLC, using a standard solution of IFN-beta as a Reference Standard.

Storage and Stability:
Lyophilized powder may be stored at -20C. Stable for 12 months at -20C. Reconstitute with sterile ddH2O, HSA or BSA. Aliquot to avoid repeated freezing and thawing. Store at -20C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.

Molecular Weight:
~22.5kD
Purity: ~98% (RP-HPLC, Anion-exchange FPLC, SDS-PAGE) Endotoxin: 0.1ng/ug (IEU/ug)
Concentration: ~1mg/ml
Form: Supplied as a lyophilized powder. No preservative added. Reconstitute with sterile dH2O, 0.1% HSA or BSA to 0.1mg/ml.

Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications without the expressed written authorization of United States Biological.
1. Response to interferon beta-1a treatment in African American multiple sclerosis patients. Arch Neurol 2005 Nov;62(11):1681-3. 2. Nephrotic syndrome in a multiple sclerosis patient treated with interferon beta 1a. Can J Neurol Sci 2005 Aug;32(3):366-8. 3. Spotlight on subcutaneous recombinant interferon-beta-1a (Rebif) in relapsing-remitting multiple sclerosis. BioDrugs 2005;19(5):323-5. 4. Interferon beta-1a overdose in a multiple sclerosis patient. Ann Pharmacother 2005 Nov;39(11):1950-2. 5. A randomized, multicentre, open-label, parallel-group trial of the tolerability of interferon beta-1a (Rebif) administered by autoinjection or manual injection in relapsing-remitting multiple sclerosis. Mult Scler 2005 Oct;11(5):585-91. 6. Benefits of high-dose, high-frequency interferon beta-1a in relapsing-remitting multiple sclerosis are sustained to 16 months: Final comparative results of the EVIDENCE trial. J Neurol Sci 2005 Dec 15;239(1):67-74.

Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.